Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2024-518916-38-00
2024-518916-38-00RecruitingPhase 2

A multicenter, randomized, double-blind, placebo-controlled, proof of concept trial to investigate the efficacy and safety of intra-articular 4P004 in subjects with knee synovitis and osteoarthritis

4moving Biotech16 sites in 4 countries84 target enrollmentStarted: August 6, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
84
Locations
16
Primary Endpoint
Change from Baseline at W4 in the weekly average of TK daily pain intensity using the WOMAC Pain subscore
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To assess the efficacy of 4P004 on OA pain in the target knee (TK) at Week (W) 4

Study Design

Allocation
Randomized
Primary Purpose
Follow-up
Masking
Double (Monitor, Subject, Analyst, Carer, Investigator)

Eligibility Criteria

Ages
18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male and female participants can take part in this study if they: • are aged between 40 and 80 years,
  • •weigh over 40 kilograms (kg),
  • •have a body mass index (BMI, the ratio of height to bodyweight) between 18.5 and 35,
  • •are able to walk unaided, or with the assistance of a cane,
  • •have had OA pain in the knee to be treated for at least 6 months before taking part,
  • •have synovitis of the knee to be treated, assessed by magnetic resonance imaging (MRI), and
  • •meet certain requirements related to their OA/synovitis diagnosis and pain levels.
  • •Please see protocol for a detailed list of inclusion criteria.

Exclusion Criteria

  • •Pregnant or breastfeeding women.
  • •Treatment with systemic corticosteroids (other than IA) at a dose greater than 10 mg prednisone or the equivalent per day for more than 7 days within 4 weeks prior to the screening visit.
  • •Please see protocol for a detailed list of exclusion criteria.
  • •Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the TK (varus > 10°, valgus > 10°) by radiography.
  • •Secondary OA such as joint dysplasia, aseptic osteonecrosis, joint infection, acromegaly, Paget disease, hemochromatosis, joint crystal disease or any inflammatory joint disease.
  • •Any known active infections including skin infections at the site injection or increased predisposition for the development of infections.
  • •Any partial knee replacement of the TK.
  • •Acute fracture or IA trauma to the TK within 12 months prior to the screening visit.
  • •Major knee surgery performed within the previous 12 months or planned during the trial.
  • •Arthroscopy of the TK within 6 months prior to the screening visit.
  • •Presence of any painful conditions that could confound accurate assessment of pain from OA in the TK, such as fibromyalgia, peripheral neuropathy or vascular insufficiency.

Outcomes

Primary Outcomes

Change from Baseline at W4 in the weekly average of TK daily pain intensity using the WOMAC Pain subscore

Change from Baseline at W4 in the weekly average of TK daily pain intensity using the WOMAC Pain subscore

Secondary Outcomes

  • Change from Baseline at W2, W6, W8, W10 and W12: - Weekly average of TK daily pain (WOMAC Pain)
  • Change from Baseline at W2, W4, W8 and W12: - NRS (0-10) pain in a nominated pain aggravating activity - WOMAC subscores and total score - Patient Global Assessment of OA (PGA-OA)
  • % of OMERACT-OARSI Responders at W2, W4, W8 and W12
  • Incidence and severity of TEAEs during the trial
  • Absolute values and changes from Baseline in: - Clinical laboratory assessments (hematology, chemistry, and urinalysis) - Vital signs (systolic and diastolic blood pressure [BP], pulse rate,)
  • Directed physical examination

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Francis Berenbaum

Scientific

4moving Biotech

Study Sites (16)

Loading locations...

Similar Trials

Recruiting
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients with Inflammatory Knee Osteoarthritis (KOA).Knee osteoarthritis
2024-514388-24-00Peptinov204
Completed
Phase 2/3
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared with Placebo in Participants with Knee Osteoarthritis Pain
2022-500228-31-01Paradigm Biopharmaceuticals (USA) Inc.80
Completed
Phase 2
A proof-of-concept study to examine QUC398 in participants with knee osteoarthritisKnee osteoarthritis
2023-509274-28-00Novartis Pharma AG76
Completed
Phase 2
Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritisKnee Osteoarthritis
2023-507559-30-00Novartis Pharma AG76
Recruiting
Phase 4
Pragmatic clinical trial to assess the utility of SLCO1B1, ABCG2, and CYP2C9 preemtive genotyping and pharmacogenetics training on the incidence of musculoskeletal adverse reactions in patients treated with statins in primary and specialized care.
2023-506814-31-01Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa1,000